New Genomic Score Predicts Survival in Cancer Patients

Patients with neuroendocrine neoplasms may see clearer prognosis insights through this new genomic tool.

Updated on Oct. 16, 2026 in Diseases

Close-up of a laboratory slide and glass vials under sterile lighting, illustrating medical diagnostic research.
Researchers at The Ohio State University Comprehensive Cancer Center have created a new genomic scoring tool to predict survival in neuroendocrine cancer patients. AI Illustration. Upload story photo >

Researchers at The Ohio State University Comprehensive Cancer Center have developed a genomic score to help predict survival outcomes in patients with neuroendocrine neoplasms. This tool may eventually assist clinicians in evaluating potential survival benefits for patients undergoing treatment with immune checkpoint inhibitors.

Why it matters

Currently, there are no validated clinical scores to predict survival outcomes for patients with neuroendocrine neoplasms. This new genomic tool aims to provide a more precise way to assess prognosis for those receiving immunotherapy.

This retrospective study of 54 patients treated with nivolumab or ipilimumab found that those with a genomic score of 2 or higher experienced longer median survival compared to those with lower scores. A validation cohort of 1,661 patients also supported the prognostic value of the score.

The players

The Ohio State University Comprehensive Cancer Center

A research and treatment facility that focuses on the study and management of cancer.

The details

The genomic score is derived from 24 functional domains consisting of 70 specific genes. It is calculated by determining the difference between positive and negative functional domain scores. Researchers established a cutoff of 2 or higher to identify patients who may experience a survival benefit from immune checkpoint inhibitors.

Timeline

  1. The study cohort received nivolumab or ipilimumab treatment between 2017 and 2023.

  2. Research results were published in 2026.

Health Landscape

This research reflects a growing trend in oncology toward utilizing genomic signatures to better tailor immunotherapy approaches for complex tumors. It highlights the shift from one-size-fits-all treatments toward precision medicine models that use genetic data to predict prognosis.

If you or a family member are undergoing immunotherapy for neuroendocrine neoplasms, the development of prognostic tools is worth discussing with your oncology team. Ask your physician about whether genomic testing or scoring tools are available to help guide care decisions at your facility.

The takeaway

Genomic profiling is increasingly providing clinicians with new ways to estimate how individual patients with rare tumors might respond to treatment. Patients should consult with their oncology specialists about how recent research into predictive scoring might eventually impact their personalized care plans.

Further reading

Learn more about the latest research and support options in our Cancer section.

Source note: This article includes information reported by Renal and Urology News.